IFM Investors’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-28,993
| Closed | -$5.33M | – | 609 |
|
|
2021
Q2 | $5.33M | Buy |
28,993
+4,507
| +18% | +$774K | 0.11% | 188 |
|
|
2021
Q1 | $3.74M | Buy |
24,486
+3,189
| +15% | +$493K | 0.1% | 211 |
|
|
2020
Q4 | $3.33M | Buy |
21,297
+3,360
| +19% | +$432K | 0.11% | 190 |
|
|
2020
Q3 | $2.05M | Buy |
17,937
+1,560
| +10% | +$168K | 0.09% | 228 |
|
|
2020
Q2 | $1.84M | Sell |
16,377
-8,269
| -34% | -$878K | 0.09% | 216 |
|
|
2020
Q1 | $2.15M | Sell |
24,646
-901
| -4% | -$88.4K | 0.1% | 202 |
|
|
2019
Q4 | $2.76M | Buy |
25,547
+626
| +3% | +$67K | 0.1% | 212 |
|
|
2019
Q3 | $2.44M | Buy |
24,921
+8,927
| +56% | +$1.01M | 0.09% | 238 |
|
|
2019
Q2 | $2.1M | Buy |
15,994
+2,042
| +15% | +$263K | 0.12% | 184 |
|
|
2019
Q1 | $1.89M | Buy |
13,952
+1,034
| +8% | +$129K | 0.12% | 180 |
|
|
2018
Q4 | $1.26M | Buy |
12,918
+1,294
| +11% | +$153K | 0.1% | 205 |
|
|
2018
Q3 | $1.62M | Buy |
11,624
+1,621
| +16% | +$203K | 0.12% | 179 |
|
|
2018
Q2 | $1.24M | Buy |
10,003
+3,088
| +45% | +$361K | 0.12% | 185 |
|
|
2018
Q1 | $771K | Buy |
6,915
+711
| +11% | +$85K | 0.11% | 202 |
|
|
2017
Q4 | $742K | Sell |
6,204
-51
| -0.8% | -$6.21K | 0.12% | 191 |
|
|
2017
Q3 | $878K | Buy |
6,255
+18
| +0.3% | +$2.44K | 0.15% | 161 |
|
|
2017
Q2 | $759K | Buy |
6,237
+1,462
| +31% | +$170K | 0.14% | 174 |
|
|
2017
Q1 | $579K | Buy |
4,775
+1,624
| +52% | +$209K | 0.15% | 165 |
|
|
2016
Q4 | $386K | Buy |
+3,151
| New | +$386K | 0.18% | 144 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM